ALECTOR INC
ALECNASDAQ🏆 #3195 by market capEarnings Nov 10US Equity
$2.24▼ $0.00 (−0.22%)
Pre-market · at closeTrack ALEC
Get earnings, price moves & breaking news on Telegram
24h▼ 0.2%
7d▲ 23.1%
14d▲ 21.7%
30d▲ 21.4%
ytd▲ 43.6%
1y▲ 46.9%
🏦Market Cap
$332M
Small Cap
📈Revenue Growth (YoY)
-82.9%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
23.8x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.21 – $2.31
- 52-Week Range
- $1.09 – $2.76
- Volume (shares)
- 87,246
- Avg Volume (shares)
- —
- Shares Outstanding
- 148.3M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $21M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- 23.8x
- EPS (TTM)
- $-1.09
- Dividend Yield
- —
- Dilution (1yr)
- +6.6%
ALECTOR INC
ALECFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$21M▼ −79.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.1%▼ −163.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$146M▲ +0.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$184M▼ −20.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
103.0M▲ +6.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$30M▲ +$39M YoY
StockOtter · stockotter.spaceAbout ALECTOR INC
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
13 analysts
Strong Buy3
Buy5
Hold3
Sell2
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.